Combination therapy efavirenz/emtricitabine/tenofovir disoproxil fumarate associated with hepatic failure.
A single pill daily fixed dose combination of Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) provides a potent and convenient treatment option for HIV/AIDS. The components have been shown to be well tolerated and are effective in randomized controlled trials. A literature search revealed no case of hepatic failure reported with this drug combination. We here in describe the 1st case of acute hepatic failure developing after 3 months of treatment with EFV/FTC/TDF in a 41 year old African American male without pre-existing liver disease or risk factors.
Department of Pathology, The University of Tennessee Health Science Center, Memphis, TN, USA. sohailqayyum@gmail.com
Sohail
S
Qayyum
Huijun
H
Dong
Dianne
D
Kovacic
Sidra
S
Sohail
Bradford
B
Waters
Camille
C
Thornton
Cathy E
CE
Corbett
D000225:Adenine / Q000009:adverse effects / Q000031:analogs & derivatives*; D000328:Adult; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives*; D004338:Drug Combinations; D000068257:Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D017093:Liver Failure / Q000139:chemically induced*; D008297:Male; D063065:Organophosphonates / Q000009:adverse effects*; D010078:Oxazines / Q000009:adverse effects*; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects*
D004338:Drug Combinations; D000068257:Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; D063065:Organophosphonates; D010078:Oxazines; D018894:Reverse Transcriptase Inhibitors; D003841:Deoxycytidine; D000225:Adenine